Sagimet Biosciences Inc (SGMT)
4.435
+0.10
(+2.19%)
USD |
NASDAQ |
May 08, 16:00
4.435
0.00 (0.00%)
After-Hours: 18:28
Sagimet Biosciences Research and Development Expense (Quarterly): 5.656M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.656M |
| September 30, 2023 | 4.958M |
| June 30, 2023 | 4.676M |
| March 31, 2023 | 4.487M |
| December 31, 2022 | 5.847M |
| Date | Value |
|---|---|
| September 30, 2022 | 6.838M |
| June 30, 2022 | 6.371M |
| March 31, 2022 | 5.863M |
| March 31, 2021 | 3.354M |
| March 31, 2020 | 3.025M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.025M
Minimum
Mar 2020
6.838M
Maximum
Sep 2022
5.108M
Average
5.307M
Median
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| 89bio Inc | 33.59M |
| Viking Therapeutics Inc | 24.10M |
| Akero Therapeutics Inc | 53.39M |
| Arrowhead Pharmaceuticals Inc | 116.49M |